THE TAPE

BeOne Medicines Ltd. American Depositary Shares

$411.29▼ −1.26%
Last close
Relative strength
78RS
of 99, against every stock▲ +4 on the month
Powering up
Developing
+26.3%
six months against Pharmaceutical Preparations
52-week range
−3.2%
from the high
$253.95$424.73
Setup
flat baseplayed out
+8.2%
against the pivot at $380.00
No report date on the calendar.
Growth REALProof SHOWN
Quarter to Sep 30, revenue +34% on a year ago
11/16 O 416.83 H 418.35 L 410.87 Vol 160.9K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS78
vs pivot+8.23%
Tightening0.88×
Dry-up0.95×
Up/down vol0.04
From high3%
failed pokeplayed out5 of 9checks
Previous breakout stopped out ▼ −9.30% in Aug
Powering up
Support and resistance
Support below
$377.67
-8.2% · tested 3× · last 12 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 7.8 weeks and fell 11% from its ceiling at its deepest. The pivot is $380.00, and the stock closed 8.2% above that pivot. Its relative strength rating is 78.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+6.7%
Three months against its industry
+28.7%
Six months against its industry
+26.3%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 4.6% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$6.6B
+33.8% year on year
Operating margin
17.8%
gross 89.4%
Net margin
13.9%
Free cash flow
$1.4B
3.1% of market cap
Price to sales
7.04×
Price to earnings
50.8×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Growth at the cost of margin: demand is there, pricing or mix is not.
Revenue
$1.9B
+10.8% QoQ · +33.8% YoY
Gross margin
88.5%
-1.3 pts QoQ
Net income
$384.7M
Positive
Free cash flow
$473.5M
Cash generating

What the numbers say

  • Good: Revenue +33.8% year over year, +10.8% on the quarter
  • Weak: Gross margin 88.5%, -1.3 points on the quarter
  • Good: Profitable: net income $385M, operating margin 22.2%
  • Good: Cash generating: operating cash flow $509M, free cash flow $474M
  • Good: Net cash $4.71B · cash $5.78B
Revenue by quarter
Free cash flow
Net income
shares +2.4% in a year · net cash $4.7B
Final read
Growth: REAL · Economic proof: SHOWN
Key question: Does the next quarter repeat this one?
The next test is gross margin: gross margin 88.5%, -1.3 points on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-06
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
168
$351,705,282 total

Sold: Ball Titus B., Lee Chan Henry, Wang Xiaodong, Wu Xiaobin, OYLER JOHN, Rosenberg Aaron, Wang Lai, Yi Qingqing, Riva Alessandro, Dugan Margaret, Sanders Corazon (Corsee) D., BAKER BROS. ADVISORS LP.

Not counted above: 43 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-09 Wang Xiaodong · Directorgift1,183
2026-11-06 Ball Titus B. · Principal Accounting Officeroption exercise880$182,644
2026-11-06 Ball Titus B. · Principal Accounting Officeroption exercise679$107,981
2026-11-06 Ball Titus B. · Principal Accounting Officersell1,533$621,712
2026-11-06 Ball Titus B. · Principal Accounting Officersell26$10,565
2026-11-05 Lee Chan Henry · SVP, General Counselsell660$264,000
2026-11-05 Lee Chan Henry · SVP, General Counselsell455$182,910
2026-10-27 Wang Xiaodong · Directoroption exercise31,028$1,144,933

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$424.00
The pole · over 5 sessions+19.4%
Through to the apex · the lines run parallel, so they never meetn/a
Touches · swing points the lines are drawn through4 up · 4 down
Length0.8 weeks
What lines up

5 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy7
Buy19
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
8w · 11%

The most recent of 4 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
BeOne Medicines Ltd. American Depositary Shares (ONC) — The Tape